Trial Profile
Phase II, Multicenter, Randomized, Adaptive, Double-blind, Placebo Controlled Study to Assess Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Year Old Spinal Muscular Atrophy (SMA) Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Olesoxime (Primary)
- Indications Spinal muscular atrophy
- Focus Registrational; Therapeutic Use
- Sponsors Roche; Trophos
- 01 Jul 2017 Primary endpoint (Motor Function Measure) has not been met, according to the results published in the Lancet Neurology.
- 01 Jul 2017 Results published in the Lancet Neurology
- 10 Mar 2014 Top-line results reported in a Trophos media release.